Translational Research & Strategic Services
Kinexum guides, designs, and manages strategic and operational solutions to the regulatory, manufacturing, nonclinical, clinical development, and business challenges necessary to take scientific discoveries to proof of concept and through the product life cycle.
Kinexum teams supplement the strengths of large and small organizations to reach high-value milestones effectively and efficiently. Kinexum specializes in crafting creative but sound and integrated solutions across scientific disciplines, therapeutic areas, product modalities, and business stages. We respond to emergencies and as well as requests for problem prevention and complex long-range planning.
News and Upcoming events
If you missed our 10/26/2018 Kinexum Public Webinar, a recording is now available:
Using Metformin to Target Aging
Featuring TAME trial co-PI's Nir Barzilai, MD, and Steve Kritchevsky, PhD
|
Kinexum executives and leading expert will attend the conferences in this section. Anyone interested in meeting them, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. . |
Recent Articles
Beyond Hemoglobin A1C Consensus Conference - July 21, 2017 Charles M. Alexander, MD
Originally, diabetes was a symptomatic condition with either diabetic ketoacidosis (DKA) in type 1 diabetes or marked weight loss, muscle wasting, and inanition in type 2 diabetes. Prognosis was dismal for both and the main difference was the rapidity of the patient’s demise.
Beyond Hemoglobin A1C Consensus Conference - July 21, 2017 - Full Article
Early on Commercial Planning Investments within the R&D Process: The Business Case - Martin Lafontaine
Commercial investments within the early phase of R&D generally rank very low on a company’s priority list. To use a sports expression, commercial investments often don’t make the cut, and get relegated to the bench.
Early on Commercial Planning Investments within the R&D Process: The Business Case - Full Article
Marketing Added Value - Arthur Santora MD, Ph.D
Fosamax was the first treatment for osteoporosis in postmenopausal women approved based phase 3 data demonstrating a reduction in the incidence of vertebral fractures. Marketing Added Value - Full Article
Marketing Added Value - Arthur Santora MD, Ph.D
Fosamax was the first treatment for osteoporosis in postmenopausal women approved based phase 3 data demonstrating a reduction in the incidence of vertebral fractures. Marketing Added Value - Full Article
